Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

PURPOSE: We previously demonstrated that thalidomide appears to add to the activity of docetaxel in metastatic castration-resistant prostate cancer (CRPC). Phase II studies combining docetaxel with bevacizumab have had substantial antitumor activity. We hypothesized that the combination of docetaxel...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Ning, Yang-Min, Gulley, James L., Arlen, Philip M., Woo, Sukyung, Steinberg, Seth M., Wright, John J., Parnes, Howard L., Trepel, Jane B., Lee, Min-Jung, Kim, Yeong Sang, Sun, Haihao, Madan, Ravi A., Latham, Lea, Jones, Elizabeth, Chen, Clara C., Figg, William D., Dahut, William L.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2010
Schlagworte:
Original Reports
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2860408/
https://ncbi.nlm.nih.gov/pubmed/20308663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.25.4524
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge